Reach Us +1(631)596-0675
PBI-4050, An Antifibrotic/metabolic Compound, Reduces Liver Steatosis, Ballooning And Fibrosis In Various Metabolic And Fibrotic Models | 109376
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

PBI-4050, an antifibrotic/metabolic compound, reduces liver steatosis, ballooning and fibrosis in various metabolic and fibrotic models

Ramon M Corpuz, B Grouix, K Hince, M Tremblay, L Geerts, F Sarra-Bournet, A Felton, F A Leblond and L Gagnon

Liminal R&D BioSciences Inc., Canada

ScientificTracks Abstracts: J Gastrointest Dig Syst

Background & Aim: Chronic liver diseases are a major cause of mortality and morbidity worldwide. Liver fibrosis is characterized by progressive accumulation of extracellular matrix proteins, resulting in destruction of the hepatic architecture. This study investigates the effect of anti-fibrotic/metabolic compound PBI-4050 on NASH and liver fibrosis using three animal models.

Methods: C57BL/6 mice were fed with either a standard or a high-fat diet for 14 weeks and treated with PBI-4050 (200 mg/kg, oral once a day) for an additional six weeks. Liver fibrosis was induced by 10% CCl4 in (2 mL/kg), twice a week for 8 weeks. Mice were treated from day 1 to 58 with oral administration of PBI-4050 (200 mg/kg). Bile Duct Ligation (BDL) was performed on male Wistar rats on day 0 and treated with PBI-4050 (200 mg/kg) (day 1 to 21).

Results: PBI-4050 reduced steatosis and ballooning as well as improved glycogen deposition in HFD-induced NASH. Extensive collagen accumulation was observed in the liver of CCl4-treated animals compared to control. PBI-4050 significantly reduced collagen deposition as measured by histological examination of the liver (H&E, Masson's trichrome staining and histomorphometric analysis of collagen deposition). Treatment with PBI-4050 also reduced liver fibrosis in BDL, as shown by a reduction of collagen in histological analysis.

Conclusion: PBI-4050 reduced liver fibrosis induced by CCl4 and BDL and attenuated steatosis and ballooning in a HFDinduced NASH model. These data suggest that PBI-4050 could be a potential novel therapy for hepatic fibrosis and NASH.

Ramon M Corpuz has completed his PhD from The University of Tokyo, Japan. He is the Pathologist of Liminal R&D BioSciences Inc (fka Prometic Biosciences Inc.), Canada. He served as a diligent and dependable Veterinary/Toxicologic/Preclinical Pathologist of GLP and non-GLP toxicology and pharmacology nonclinical studies (100+ studies) for more than 10 years. He is a Member of the Society of Toxicologic Pathology with an American College of Veterinary Pathologists board eligibility, a Member of the Charles Louis Davis DVM Foundation for the Advancement of Veterinary Pathology (2007-2009), a Board of Director of the Philippine College of Veterinary Pathology (1998-2000) and a Member of the Japanese Veterinary Science Society (1990-1994). He was a former Monbusho Scholar of the Japanese Government (1987-1994), a Scholar of the International Congress of Virology (1993, Glasgow, UK) and a Scholar of the Philippine Veterinary Drug Association (1981-1982).

E-mail: [email protected]